Developing cell based therapeutic products.
Cure Disease Like Never Before
Platforms
TriSafe Platform:
Proprietery Alternation on the Affinity of scFv to Reduce Non-Specificity.
TriSure Platform :
Integrated Proprietary Modulator to Change the Inhibitory Landscape of Tumor Micro-Environment.
TriExpan Platform:
Proprietary Co-Stimulator Factors to Increase the Persistence, Activation and Expansion of T cells.
TriGration Platform:
Proprietary Guider for Directional T Cell Migration and Killing.
FIT Platform:
Proprietary Fast-In-Transfer Technology for Efficient Gene Delivery and Immune Cell Manufacture.
Program： ARM011
Non viral approach for blood malignancies
Stage- Human Trial/IND.
Program：ARM022
Unique Design CAR-T for Blood Malignancies.
Stage- Human Trial/IND.
Program：ARM003
Renovated CAR-T for Solid Tumors.
Stage- Human Trial/IND
Program：ARM004
Retro-COMBO for solid tumors
Stage- Preclinical.
Program：ARM005
Dual Target CAR-T for Liquid Tumors Stage- Preclinical/IND.
.
Pipelines
